Catalog No.
DHH37201
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Membrane antigen MN, P54/58N, Carbonic anhydrase 9, Renal cell carcinoma-associated antigen G250, CA-IX, CAIX, pMW1, Carbonic anhydrase IX, RCC-associated antigen G250, Carbonate dehydratase IX, CA9, MN, G250
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q16790
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
WX-G250, cG250, CAS: 916138-87-9
Clone ID
Girentuximab
Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo, PMID: 30487460
Kidney cancer: Finding a niche for girentuximab in metastatic renal cell carcinoma, PMID: 27349371
Lesion detection by [ 89 Zr]Zr-DFO-girentuximab and [ 18 F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma, PMID: 31172212
Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with 111 In-girentuximab, PMID: 31768601
Positron Emission Tomography/Computed Tomography with 89 Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion, PMID: 29730017
Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial, PMID: 27787547
Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma, PMID: 23453421
Targeted PET/CT imaging for clear cell renal cell carcinoma with radiolabeled antibodies: recent developments using girentuximab, PMID: 33742975
Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC, PMID: 25748241
Preclinical validation of 111 In-girentuximab-F(ab') 2 as a tracer to image hypoxia related marker CAIX expression in head and neck cancer xenografts, PMID: 28789809
Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab, PMID: 24752673
Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma, PMID: 24396030
CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models, PMID: 31827111
Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer, PMID: 23204838
Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma, PMID: 26706103
Girentuximab bringt keinen klinischen Benefit, PMID: 28854471
Phase I study to assess safety, biodistribution and radiation dosimetry for 89 Zr-girentuximab in patients with renal cell carcinoma, PMID: 33651116
Re: Constantijn H.J. Muselaers, Otto C. Boerman, Egbert Oosterwijk, Johannes F. Langenhuijsen, Wim J.G. Oyen, Peter F.A. Mulders. Indium-111-labeled girentuximab immunospect as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol 2013;63:1101-6, PMID: 23849417
Reply to John Samuel Banerji's letter to the editor re: Constantijn H.J. Muselaers, Otto C. Boerman, Egbert Oosterwijk, Johannes F. Langenhuijsen, Wim J.G. Oyen, Peter F.A. Mulders. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol 2013;63:1101-6, PMID: 23859982
Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study, PMID: 27103404
Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma, PMID: 22980441
Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors, PMID: 26878088
Molecular imaging of urogenital diseases, PMID: 24484747
Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models, PMID: 30550290
Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management, PMID: 32998233
Carbonic Anhydrase Inhibition and the Management of Hypoxic Tumors, PMID: 28926956
Diagnostic Challenges of Kidney Cancer: A Systematic Review of the Role of Positron Emission Tomography-Computerized Tomography, PMID: 27140072
PET/CT with (124)I-cG250: great potential and some open questions, PMID: 25055257
Molecular imaging of renal cell carcinoma, PMID: 18992614
Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study, PMID: 29721070
The role of molecular imaging in the characterization of renal masses, PMID: 29319547
Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?, PMID: 24215158
Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts, PMID: 30464696
Noninvasive determination of renal tumor histology utilizing molecular imaging, PMID: 27888980
Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma, PMID: 23638744
Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial, PMID: 23213092
G250: a carbonic anhydrase IX monoclonal antibody, PMID: 15717944
Antibody-based therapeutics to watch in 2011, PMID: 21051951
Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma, PMID: 23759990
Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule, PMID: 25434612
Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy, PMID: 20359812
Perioperative Management of Localized Kidney Cancer: Watching and Waiting, PMID: 27787546
Inhibition of V-ATPase and carbonic anhydrases as interference strategy with tumor acidification processes, PMID: 22360559
Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non-renal cancer model, PMID: 25230982
Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma, PMID: 27418270
6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland, PMID: 21441785
CA IX stratification based on cancer treatment: a patent evaluation of US2016/0002350, PMID: 27575256
Management of urological malignancies: Has positron emission tomography/computed tomography made a difference?, PMID: 25624571
Fabrication of mAb G250-SPIO molecular magnetic resonance imaging nanoprobe for the specific detection of renal cell carcinoma in vitro, PMID: 24999987
PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors, PMID: 20554724
For research use only. Not for human or drug use.
